Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

(2020) Jean-Jacques Kiladjian et al.   Lancet Haematology

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

(2020) Lucio Verdoni et al.   LANCET

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

(2020) Carl C. Crodel et al.   LEUKEMIA

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells

(2020) Mariusz Z. Ratajczak et al.   LEUKEMIA

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

(2020) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

(2020) Francesca Romana Spinelli et al.   Science Immunology

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis

(2019) Sabrin Albeituni et al.   BLOOD

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

(2019) Asra Ahmed et al.   Lancet Haematology

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation

(2019) Perner et al.   Cells

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation

(2018) Bärbel Edelmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Impact of tofacitinib treatment on human B-cells in vitro and in vivo

(2017) Marta Rizzi et al.   JOURNAL OF AUTOIMMUNITY

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

(2016) S Koschmieder et al.   LEUKEMIA

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

(2015) Clodagh Keohane et al.   BRITISH JOURNAL OF HAEMATOLOGY

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function

(2015) F Perner et al.   LEUKEMIA

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

(2013) M Massa et al.   LEUKEMIA

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE